Pacific Edge is pleased to confirm that the company has reached commercial agreement with Taranaki District Health Board (DHB) for the use of Cxbladder products across the clinical pathway in the detection, management, and monitoring of bladder cancer patients. This further extends Cxbladder's national coverage delivered through New Zealand’s public healthcare providers.

The Taranaki DHB is based in New Plymouth and covers an area including Stratford and Hawera, serving a population of over 124,000. The region has a higher than average number of residents aged 50 years or older, and is predominantly a rural population with a strong Maori presence.

Under the agreement, Taranaki DHB will provide access to Cxbladder Triage, Detect, Resolve and Monitor tests for patients throughout the region, with Cxbladder urine sampling systems sent to Taranaki Pathology collection locations to facilitate ease of access and specimen collection.

Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: “This agreement furthers the reach of Cxbladder into regional New Zealand, helping physicians with their evaluation of patients who present with haematuria (blood in the urine) at our busy public hospitals. Pacific Edge’s suite of Cxbladder products are now well-placed to extend their coverage under a national clinical pathway as New Zealand’s health system consolidates towards the Maori Health Authority and Health NZ next year.